PTEN and metastatic neoplasm: Since there are numerous differences in the analysis of PTEN expression, including IHC scoring algorithms and inconsistent expression in primary and metastatic tumor samples, loss of PTEN expression cannot be reliably regarded as a negative biomarker of the efficacy of anti-EGFR moAbs.